rifampin has been researched along with Ascariasis* in 1 studies
1 other study(ies) available for rifampin and Ascariasis
Article | Year |
---|---|
Predictors of therapeutic failure among patients with acute brucellosis treated by dual therapy with doxycycline-rifampin.
To determine the frequency of therapeutic failure among patients with acute and subacute brucellosis and to explore the predictors of failure.. The study included 213 consecutive, naïve patients with acute and subacute brucellosis. All participants underwent clinical evaluation, chest radiography, stool microscopic examination and interferon-gamma release assay. Patients received the WHO-recommended therapy of doxycycline 200 mg/day and rifampin 900 mg/day, for 6 weeks.. Mean age of the study population was 39.8 ± 12.2 years; 64.8% of them were males. The therapeutic failure rate was 16.4%. Adverse effects were reported by 13.1%. Multivariate analysis of factors associated with therapeutic failure revealed latent tuberculosis infection (LTBI) (OR 3.1, 95% CI, 1.9-24.6, P: 0.009), ascariasis (OR 2.6, 95% CI 1.5-17.9, P: 0.012), and the use of acid suppressive therapy (OR 2.1, 95% CI 1.2-19.5, P: 0.037) as the predictors of therapeutic failure.. The prevalence of therapeutic failure among the Egyptian patients with acute/subacute brucellosis is increasing. Predictors of therapeutic failure are LTBI, ascariasis, and the use of acid suppressive therapy. Topics: Acute Disease; Adult; Anti-Bacterial Agents; Ascariasis; Brucellosis; Doxycycline; Drug Therapy, Combination; Egypt; Female; Humans; Latent Tuberculosis; Male; Middle Aged; Multivariate Analysis; Prognosis; Prospective Studies; Rifampin; Treatment Failure; Young Adult | 2019 |